France· FR:67695203
PEMAZYRE 13,5 mg, comprimé
A medicinal product containing pémigatinib, registered in France by INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PÉMIGATINIB
- Manufacturer
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930223710plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)EUR 6.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pémigatinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPEMAZYREIncyte Biosciences Distribution B.V., Amsterdam
- SwitzerlandPemazyre 13,5 mg, comprimésIncyte Biosciences International Sàrl
- United StatesPEMAZYREIncyte Corporation
- United KingdomPemazyre 13.5mg tabletsIncyte Biosciences UK Ltd
- CanadaPEMAZYREINCYTE CORPORATION
- IcelandPemazyreIncyte Biosciences Distribution B.V.
- NetherlandsPemazyre 13,5 mg, tablettenIncyte Biosciences Distribution B.V.
- NorwayPemazyreIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pemazyre
- Liechtenstein · Pemazyre
- Norway · Pemazyre
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/80bcc4a3-a94b-46c2-a179-d6b0e98bc4d1 GET /v1/drugs/80bcc4a3-a94b-46c2-a179-d6b0e98bc4d1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67695203",
"date_amm": "2021-03-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1535",
"substance": "PÉMIGATINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about pémigatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.